Literature DB >> 9684795

Population pharmacokinetics of recombinant factor VIIa in volunteers anticoagulated with acenocoumarol.

P Girard1, P Nony, E Erhardtsen, S Delair, P Ffrench, M Dechavanne, J P Boissel.   

Abstract

This study establishes a population PK model for FVII clotting activity (FVII:C) after injection of recombinant activated factor VII (rFVIIa) to healthy volunteers. Twenty eight volunteers, anticoagulated with acenocoumarol, received one or two rFVIIa injections, with dose ranging from 5 to 320 microg/kg. The FVII:C kinetic was fitted to a 2 compartment model, with continuous "endogenous perfusion" mimicking endogenous activity. Estimated clearance was 2.4 1/h (20% inter-individual variability and 9% inter-period variability). The volume of distribution at steady-state appeared to be significantly dose dependent: 78 ml/kg for doses < or = 20 microg/kg and 88 ml/kg for doses > 20 microg/kg respectively, with 16% inter-individual variability. The dose producing 50% of the maximum drop of INR was estimated to be 2.2 microg/kg. The model will be used to better define the dosage regimen for future clinical developments.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9684795

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  8 in total

Review 1.  Recombinant factor VIIa (Eptacog Alfa): a review of its use in congenital or acquired haemophilia and other congenital bleeding disorders.

Authors:  M Asif A Siddiqui; Lesley J Scott
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 2.  Recombinant factor VIIa: a review on its clinical use.

Authors:  Massimo Franchini
Journal:  Int J Hematol       Date:  2006-02       Impact factor: 2.490

3.  Redistribution and hemostatic action of recombinant activated factor VII associated with platelets.

Authors:  Irene Lopez-Vilchez; Ulla Hedner; Carmen Altisent; Maribel Diaz-Ricart; Gines Escolar; Ana M Galan
Journal:  Am J Pathol       Date:  2011-06       Impact factor: 4.307

Review 4.  Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia.

Authors:  S Björkman; E Berntorp
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 5.  Mechanistic implications for the use and monitoring of recombinant activated factor VII in trauma.

Authors:  Anthony E Pusateri; Myung S Park
Journal:  Crit Care       Date:  2005-10-07       Impact factor: 9.097

6.  Pharmacokinetics of recombinant activated factor VII in trauma patients with severe bleeding.

Authors:  Thomas Klitgaard; Rene Tabanera y Palacios; Kenneth D Boffard; Philip T C Iau; Brian Warren; Sandro Rizoli; Rolf Rossaint; Yoram Kluger; Bruno Riou
Journal:  Crit Care       Date:  2006       Impact factor: 9.097

7.  Overview of the human pharmacokinetics of recombinant activated factor VII.

Authors:  Thomas Klitgaard; Tina G Nielsen
Journal:  Br J Clin Pharmacol       Date:  2007-10-24       Impact factor: 4.335

8.  Pharmacological characteristics of a novel, recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP).

Authors:  S Zollner; D Schuermann; E Raquet; J Mueller-Cohrs; T Weimer; I Pragst; G Dickneite; S Schulte
Journal:  J Thromb Haemost       Date:  2014-02       Impact factor: 5.824

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.